141 related articles for article (PubMed ID: 38635764)
1. Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States.
Waldron C; Ito S; Wang D; Allen C; Viswanathan G; Bona RD; Cuker A; Goshua G
Blood; 2024 May; 143(22):2332-2335. PubMed ID: 38635764
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL
Wien Klin Wochenschr; 1999 Mar; 111(5):181-91. PubMed ID: 10226348
[TBL] [Abstract][Full Text] [Related]
3. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results.
Leebeek FWG; Peyvandi F; Escobar M; Tiede A; Castaman G; Wang M; Wynn T; Baptista J; Wang Y; Zhang J; Mellgård B; Özen G
Blood; 2022 Jul; 140(2):89-98. PubMed ID: 35439298
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL
Haemophilia; 1998; 4 Suppl 3():53-62. PubMed ID: 10028320
[TBL] [Abstract][Full Text] [Related]
5. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease.
Turecek PL; Gritsch H; Pichler L; Auer W; Fischer B; Mitterer A; Mundt W; Schlokat U; Dorner F; Brinkman HJ; van Mourik JA; Schwarz HP
Blood; 1997 Nov; 90(9):3555-67. PubMed ID: 9345039
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease.
Hancock JM; Escobar MA
Expert Rev Hematol; 2023 Mar; 16(3):157-161. PubMed ID: 36861346
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial.
Leebeek FWG; Peyvandi F; Tiede A; Castaman G; Escobar M; Wang M; Zülfikar B; Susen S; Miesbach W; Wang S; Wang Y; Zhang J; Özen G
Eur J Haematol; 2023 Jul; 111(1):29-40. PubMed ID: 36823994
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.
Mannucci PM; Kempton C; Millar C; Romond E; Shapiro A; Birschmann I; Ragni MV; Gill JC; Yee TT; Klamroth R; Wong WY; Chapman M; Engl W; Turecek PL; Suiter TM; Ewenstein BM;
Blood; 2013 Aug; 122(5):648-57. PubMed ID: 23777763
[TBL] [Abstract][Full Text] [Related]
9. In vitro field study and worldwide survey assessing how clinical haemostasis laboratories analyse recombinant and plasma-derived von Willebrand factor products.
Turecek PL; Ilk R; Gritsch H
Haemophilia; 2024 Jan; 30(1):151-160. PubMed ID: 37926687
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3.
Bauer A; Friberg-Hietala S; Smania G; Wolfsegger M
J Blood Med; 2023; 14():399-411. PubMed ID: 37332615
[TBL] [Abstract][Full Text] [Related]
11. Recombinant vs plasma-derived von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease.
Machin N; Ragni MV
Blood Adv; 2020 Jul; 4(14):3234-3238. PubMed ID: 32692849
[TBL] [Abstract][Full Text] [Related]
12. Comparison of plasma-derived and recombinant von Willebrand factor by atomic force microscopy.
Seyfried BK; Friedbacher G; Rottensteiner H; Schwarz HP; Ehrlich H; Allmaier G; Turecek PL
Thromb Haemost; 2010 Sep; 104(3):523-30. PubMed ID: 20589314
[TBL] [Abstract][Full Text] [Related]
13. Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease.
Gritsch H; Schrenk G; Weinhappl N; Mellgård B; Ewenstein B; Turecek PL
J Blood Med; 2022; 13():649-662. PubMed ID: 36405429
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor.
Colling ME; Friedman KD; Dzik WH
Clin Appl Thromb Hemost; 2019; 25():1076029619873976. PubMed ID: 31496264
[TBL] [Abstract][Full Text] [Related]
15. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.
Gill JC; Castaman G; Windyga J; Kouides P; Ragni M; Leebeek FW; Obermann-Slupetzky O; Chapman M; Fritsch S; Pavlova BG; Presch I; Ewenstein B
Blood; 2015 Oct; 126(17):2038-46. PubMed ID: 26239086
[TBL] [Abstract][Full Text] [Related]
16. Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease.
Singal M; Kouides PA
Drugs Today (Barc); 2016 Dec; 52(12):653-664. PubMed ID: 28276537
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Von Willebrand factor concentrate in 2A Von Willebrand disease: comparison to plasma-derived Von Willebrand factor concentrate therapy.
Rajpurkar M; Frey MJ; Sabo C; Hollon W
Blood Coagul Fibrinolysis; 2019 Jun; 30(4):168-170. PubMed ID: 31090598
[TBL] [Abstract][Full Text] [Related]
18. Clinical Efficacy and Safety of Fanhdi
Jiménez-Yuste V; Alvarez-Román MT; Palomo Bravo Á; Galmes BJ; Nieto Hernández MDM; Benítez Hidalgo O; Marzo Alonso C; Pérez González NF; Coll J; Núñez R; Carrasco M; García Candel F; Gonzalez-Porras JR; Hernández García C; Varó Castro MJ; Mir R
Clin Appl Thromb Hemost; 2022; 28():10760296221074348. PubMed ID: 35108125
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.
Peyvandi F; Mamaev A; Wang JD; Stasyshyn O; Timofeeva M; Curry N; Cid AR; Yee TT; Kavakli K; Castaman G; Sytkowski A
J Thromb Haemost; 2019 Jan; 17(1):52-62. PubMed ID: 30362288
[TBL] [Abstract][Full Text] [Related]
20. Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor.
Peyvandi F; Kouides P; Turecek PL; Dow E; Berntorp E
Blood Rev; 2019 Nov; 38():100572. PubMed ID: 31229334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
